Clinical Value Of Combined Detection Research Articles

Clinical value of combined detection of Carcinoembryonic Antigen and CA125 in the diagnosis of non-small cell lung cancer combined with Malignant Pleural Effusion.

To investigate the clinical value of combined detection of carcinoembryonic antigen(CEA) and CA125 in the diagnosis of non-small cell lung cancer(NSCLC) combined with malignant pleural effusion. This was retrospective research. Fifty-six NSCLC patients combined with malignant pleural effusion in Baoding No.1 Hospital, China, from January 2020 to January 2022 were recruited as the malignant group, and another 56 NSCLC patients combined with pleural effusion in the same period were recruited as the benign group. Pleural effusion and serum specimens were collected from both groups and their carcinoembryonic antigen (CEA), carbohydrate antigen 125(CA125) and SP70 antigen levels were measured respectively. The differences in index levels between the two groups were compared, and the value of the index in diagnosing NSCLC combined with malignant pleural effusion was analyzed. The positive rates of CEA, CA125 and SP70 antigen in pleural effusion were higher in the malignant group than in the benign group (p>0.05); The positive rates of CEA and CA125 in the malignant group were higher than those in the benign group (p>0.05), with no statistically significant difference between the two groups in the positive rates of SP70 antigen (p>0.05). ROC curve analysis revealed the value of serum CEA and CA12 in the diagnosis of NSCLC combined with malignant pleural effusion, while serum SP70 antigen had no diagnostic value (p>0.05). The combined detection of CEA, CA125 and SP70 antigen boasts a higher diagnostic value for NSCLC-mediated pleural effusion, with higher diagnostic value than the combined detection of serum indexes.

Clinical Value of Combined Detection of Serum sTim-3 and CEA or CA19-9 for Postoperative Recurrence of Colorectal Cancer Diagnosis.

The present study aimed to evaluate the clinical value of Combined Detection of serum soluble T-cell immunoglobulin 3 (sTim-3) with carcinoembryonic antigen (CEA) or glycotype antigen 19-9 (CA19-9) for Postoperative Recurrence of Colorectal Cancer (CRC) Diagnosis. The serum sTim-3 was measured by highly sensitivity TRFIA, and serum CEA and CA19-9 were obtained through the collection of clinical data. Quantitative detection of serum sTim-3, CEA, CA19-9 in 90 patients after the CRC surgery (52 postoperative recurrence and 38 no-postoperative recurrence), 21 patients with colorectal benign tumors, and 67 healthy controls. To analyze the clinical diagnostic value of combined detection of sTim-3 with CEA or CA19-9 to test whether patients have recurrence after CRC surgery. The sTim-3 (15.94±11.24ng/mL) in patients after CRC surgery was significantly higher than in healthy controls (8.95±3.34ng/mL) and colorectal benign tumors (8.39±2.28ng/mL) (P < 0.05), and sTim-3 (20.33±13.04ng/mL) in CRC postoperative recurrent group was significantly higher than in the group without recurrence after CRC surgery (9.94±2.36ng/mL) (P < 0.05). In terms of detecting postoperative recurrence after CRC surgery, combined detection of sTim-3 and CEA (AUC: 0.819, sensitivity: 80.77%, specificity: 65.79%), sTim-3 and CA19-9 test (AUC: 0.813, sensitivity: 69.23%, specificity: 97.30%) was significantly better than the CEA single test (AUC: 0.547, sensitivity: 63.16%, specificity: 48.08%) and CA19-9 single test (AUC: 0.675 sensitivity: 65.38%, specificity: 67.57%), Delong test P < 0.05. The efficacy of CEA and CA19-9 single test was not optimal, and the combination of sTim-3 in serum could significantly improve the sensitivity and specificity of detecting patient recurrence after CRC surgery.

Clinical value of combined detection of thrombus precursor protein and P-selectin in the diagnosis of acute coronary syndrome

Clinical value of combined detection of thrombus precursor protein and P-selectin in the diagnosis of acute coronary syndrome

Clinical Value of Peripheral Blood Circulating Tumor Cells and Cell-Free DNA Combined Detection in Triple-Negative Breast Cancer

Objective: To determine the clinical value of combined detection of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in peripheral blood of patients with triple-negative breast cancer. Method: 41 patients with breast cancer admitted to the First Central Hospital of Baoding from January 2020 to December 2021 were selected and recruited into the experimental group, 42 patients with benign breast cancer admitted during the same period were recruited into the conditional control group, and 41 healthy patients admitted during the same period were recruited into the blank control group. The positive rate of peripheral blood CTCs, the level of cfDNA, and the diagnostic efficacy of peripheral blood CTCs, cfDNA alone and the combination thereof for breast cancer were analyzed. Result: The positive rates of peripheral blood CTCs in the experimental group, the conditional control group, and the blank control group were 43.90%, 11.90%, and 9.74%, respectively, and there was significant difference among the groups. The levels of cfDNA in peripheral blood of the experimental group, the conditional control group, and the blank control group were 0.26 ± 0.08 bp, 0.17 ± 0.03 bp, and 0.15 ± 0.04 bp, respectively, which were statistically significant. The detection levels of 100 bp hTERT/ng·ml-1 and 241 bp hTERT/ng·ml-1 in the experimental group were significantly higher than those in the conditional control group and the blank control group. The accuracy of peripheral blood CTCs detection in the three groups was 66.21%, the accuracy of cfDA241 bp / 100 bp hTERT detection was 80.41%, and the accuracy of combined detection of peripheral blood CTCs and cfDNA was 94.03%. Conclusion: The clinical application of peripheral blood CTCs combined with cfDNA level detection can increase detection accuracy, provide data support for clinicians, and improve the clinical diagnostic effect of triple-negative breast cancer.

Clinical Application Value of Combined Detection of CG and TBA in Differential Diagnosis of Hepatobiliary System Diseases

Objective: To understand the clinical value of combined detection of cholyglycine CG and TBA in differential diagnosis of hepatobiliary diseases. Methods: Serum samples from 50 healthy people were collected as healthy control group. According to the latest disease diagnosis and treatment plan, 58 cases of HBV asymptomatic carrier group, 17 cases of viral hepatitis group, 49 cases of cirrhosis group, 50 cases of primary liver cancer group and 50 cases of other hepatobiliary diseases groups were collected respectively. The concentration levels of cholyglycine and total bile acid in each group were detected, and the differences among each group were compared. Results: By statistical analysis, serum CG concentration in viral hepatitis group, cirrhosis group, primary liver cancer group and other hepatobiliary diseases group was significantly higher than that in asymptomatic HEPATITIS B carriers and healthy control group, the differences were statistically significant (p 0.05). There was no significant difference in CG concentration among viral hepatitis group, liver cirrhosis group, primary liver cancer group and other hepatobiliary diseases group (p > 0.05). The serum TBA levels of asymptomatic carriers, viral hepatitis group, cirrhosis group, primary liver cancer group and other hepatobiliary system diseases group were significantly higher than those of healthy control group, the difference was statistically significant, p 0.05. Conclusion: Serum CG expression can not only detect liver lesions, but also distinguish different liver lesions. The positive rate of CG combined with TBA detection in patients with hepatobiliary diseases is significantly higher than that of single CG index detection. CG combined with TBA detection can significantly improve the sensitivity and accuracy of the diagnosis of hepatobiliary diseases, which is worthy of popularization and application.

Combined detection of circulating tumor cells, \u03b1-fetoprotein heterogene-3 and \u03b1-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation

BackgroundEarly diagnosis can significantly improve treatment outcomes for hepatocellular carcinoma (HCC) patients. Currently, the dosage of serum alpha fetoprotein (AFP) is widely used in the diagnosis of HCC, but this biomarker has low specificity and may cause false positive or false negative results. Thus, it’s necessary to find and validate other serum tumor markers that in association for AFP would increase the sensitivity and the specificity in the HCC diagnosis. This study investigated the predictive value of combined of AFP, AFP-L3, and Circulating tumor cells (CTCs).MethodsA total of 105 patients with HCC after microwave ablation (MWA) were divided into non recurrence group, recurrence group, good prognosis (CR + PR group, CR: Complete remission, PR: Partial remission) and poor prognosis (SD + PD group, SD: Stable, PD: Progression). ROC curve was used to analyze the short-term efficacy, prognosis and clinical value of combined detection of the three indicators in predicting postoperative recurrence of HCC patients with MWA.ResultsThe positive rate of serum CTCs, AFP-L3 and AFP combined detection in the diagnosis of HCC is higher than that of single index and two index detection. The AUC, sensitivity and specificity of serum CTCs, AFP-L3 and AFP combined detection was better than that of single index and two indexes in patients with HCC after MWA.ConclusionsCombined detection of AFP, AFP-L3, and CTCs can effectively make up for the shortcomings of the detection with single and pairwise indicators. It can’t only diagnose HCC in early, but also has a high clinical value of predicting the short-term efficacy, prognosis and recurrence of HCC patients after MWA treatment.

Clinical diagnostic value of combined detection of IMA, D-D and MCP-1 in acute myocardial infarction.

The aim of the study was to analyze the clinical value of the combined detection of ischemia-modified albumin (IMA), D-dimer (D-D) and monocyte chemoattractant protein-1 (MCP-1) in the diagnosis of acute myocardial infarction (AMI). Altogether 87 patients with AMI from January 2017 to January 2018 were enrolled in the AMI group, and 82 patients without coronary artery disease were included in the control group. The serum levels of IMA, D-D, MCP-1, cardiac troponin (CTnT) and high-sensitivity C-reactive protein (hs-CRP) in the two groups were detected by ELISA. The blood lipids of the two groups and the levels of IMA, D-D, MCP-1 after treatment were detected. The association between IMA, D-D, MCP-1, CTnT, hs-CRP and blood lipid in patients with AMI was analyzed. The values of IMA, D-D, and MCP-1 alone and combined in the diagnosis of AMI were analyzed by ROC curve. The levels of IMA, D-D, MCP-1, CTnT and hs-CRP in the AMI group were significantly higher than those in the control group (P<0.05). The levels of IMA, D-D and MCP-1 in the patients with poor prognosis were significantly higher than those of the good prognosis group (P<0.05). The changes of IMA, D-D and MCP-1 levels were positively correlated with the levels of CTT and hs-CRP (P<0.05). The AUC, specificity and sensitivity of patients with AMI diagnosed with MCP-1 alone were 0.8084, 81.61 and 69.51%, respectively. Those of patients diagnosed by D-D were 0.7302, 59.77 and 81.71%, those of patients diagnosed by IMA alone were 0.7289, 58.62 and 80.49%, and those of patients detected by the combination of MCP-1, D-D and IMA were 0.9047, 58.62 and 93.90%. In conclusion, the levels of IMA, D-D and MCP-1 in AMI patients are higher than those in the control group. The levels of IMA, D-D and MCP-1 were positively correlated with CTnT and hs-CRP levels in AMI patients. Combined detection of IMA, D-D, and MCP-1 can improve the accuracy.

血清PGI、PGII、PGR、G-17水平与Hp-IgG联合检测对胃癌早期诊断的临床价值分析

Objective To investigate the clinical value of combined detection of serum pepsinogen (PG)Ⅰ, PGⅡ, PGⅠ/PGⅡ (PGR), gastrin-17 (G-17) and IgG anti-Helicobacter Pylori (IgG anti-Hp) in the diagnosis of early gastric cancer. Methods One hundred and twenty patients with gastric cancer (early gastric cancer group), 60 patients with atrophic gastritis (atrophic gastritis group) and 120 healthy volunteers (control group) who were examined or treated in our hospital from January 2018 to June 2019 were selected as the subjects. The levels of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp were compared among the three groups. The indicators and combined diagnostic value were analyzed by receiver operating characteristic (ROC) curve. Results The levels of PGⅠ in early gastric cancer group, atrophic gastritis group and control group were (59.85±8.59)ng/ml, (72.19±9.89)ng/ml, (96.83±8.66)ng/ml, with statistically significant difference (F=530.504, P<0.001). The levels of PGⅡ in the three groups were (23.19±2.45)ng/ml, (20.60±4.19)ng/ml, (16.52±3.34)ng/ml, with statistically significant difference (F=130.085, P<0.001). The levels of PGR in three groups were 2.78±0.69, 4.33±0.95, 6.21±1.46, with statistically significant difference (F=288.801, P<0.001). The levels of G-17 in the three groups were (77.04±10.09)ng/ml, (64.69±7.22)ng/ml, (55.91±8.32)ng/ml, with statistically significant difference (F=170.770, P<0.001). The levels of IgG anti-Hp in the three groups were (70.23±8.11)IU, (58.30±9.37)IU, (33.00±5.24)IU, with statistically significant difference (F=778.431, P<0.001). The levels of serum PGⅠand PGR in early gastric cancer group and atrophic gastritis group were significantly lower than those in control group (all P<0.05). The levels of serum PGⅠand PGR in early gastric cancer group were significantly lower than those in atrophic gastritis group (both P<0.05). While serum PGⅡ, G-17 and IgG anti-Hp in early gastric cancer group and atrophic gastritis group were significantly higher than those in control group (all P<0.05). The levels of PGⅡ, G-17 and IgG anti-Hp in gastric cancer group were significantly higher than those in atrophic gastritis group (all P<0.05). According to the ROC curve, the critical value of serum PGⅠ diagnosis was 73.11 ng/ml, the sensitivity was 63.33%, the specificity was 83.33%, and the area under the curve (AUC) was 0.801. The critical value of serum PGⅡ diagnosis was 19.55 ng/ml, the sensitivity was 75.83%, the specificity was 72.22%, and the AUC was 0.760. The critical value of serum PGR diagnosis was 4.60, the sensitivity was 82.50%, the specificity was 77.22%, and the AUC was 0.816. The critical value of serum G-17 diagnosis was 64.33 ng/ml, the sensitivity was 64.17%, the specificity was 65.56%, and the AUC was 0.631. The critical value of IgG anti-Hp diagnosis was 53.80 IU, the sensitivity was 59.17%, the specificity was 75.00%, and the AUC was 0.708. At the critical tangent point, the sensitivity, specificity and AUC of PG I + IgG anti-Hp were 69.17%, 76.67% and 0.754 respectively; the sensitivity, specificity and AUC of PGR + IgG anti-Hp were 88.33%, 74.44% and 0.798 respectively; the sensitivity, specificity and AUC of G-17 + IgG anti-Hp were 71.67%, 65.56% and 0.718 respectively. The sensitivity of joint detection of the five indexes was 92.50%, the specificity was 72.22%, and the AUC was 0.869. The sensitivity of joint detection was significantly higher than that of individual detection (all P<0.05), and the AUC of joint detection was significantly higher than that of individual indexes (Z=1.848, P=0.032; Z=3.145, P=0.001; Z=1.688, P=0.046; Z=7.726, P<0.001; Z=4.931, P<0.001; Z=3.188, P=0.001; Z=1.783, P=0.037; Z=4.534, P<0.001). Conclusion The combined detection of serum PGⅠ, PGⅡ, PGR, G-17 and IgG anti-Hp can improve the sensitivity of gastric cancer diagnosis and it is of great significance and value for early diagnosis of gastric cancer. Key words: Stomach neoplasms; Pepsinogens; Helicobacter Pylori; Gastrin-17

Clinical value of plasma BNP combined with Tei index in evaluating left ventricular function in children with congenital heart disease before interventional therapy

Objective To explore the clinical value of combined detection of plasma BNP and Tei index in evaluating left ventricular function in children with congenital heart disease before interventional therapy. Methods From April 2017 to April 2019, a total of 60 children with congenital heart disease who were going to receive interventional therapy in Dachong Hospital of Zhongshan and Boai Hospital of Zhongshan were selected as observation subjects, and the patients were divided into cardiac function class Ⅰ group and cardiac function class Ⅱ group according to NYHA cardiac function classification, with 30 cases in each group.At the same time, 30 normal children were selected as healthy control group.The differences of plasma BNP concentration, left ventricular ejection fraction(LVEF) and left ventricular Tei index in different group were compared.The correlation between the plasma concentration and the cardiac function was investigated, and the correlation between the plasma BNP concentration and the Tei index was analyzed. Results The concentration of serum BNP[(6.8±1.2)ng/L] and the Tei index of left ventricle (0.63±0.08) in the cardiac function class Ⅱ group were significantly higher than those in the cardiac function class Ⅰ group[(5.4±1.3)ng/L, (0.48±0.11)], and the differences were statistically significant (t=1.92, 3.01, all P<0.05). These two indicators of the two groups were higher than those of the healthy control group[(3.7±1.5)ng/L, (0.33±0.09)], the differences were statistically significant(t=2.14, 2.28, 4.19, 6.14, all P<0.05). In addition, the LVEF of the cardiac function class Ⅱ group was significantly lower than that of the cardiac function class Ⅰ group(t=5.00, P<0.05), and the LVEF of the two groups were significantly lower those that of the healthy control group(t=10.32, 4.51, all P<0.05). With the increase of severity of cardiac insufficiency, the BNP and Tei index gradually increased(F=3.054, 3.491, all P<0.05), and the LVEF value decreased gradually (F=12.50, P<0.05). At the same time, the linear correlation analysis showed that the plasma BNP concentration had a positive correlation with the left ventricular Tei index(r=0.69, P<0.01). Conclusion Plasma BNP combined with Tei index can quickly and accurately assess the left ventricular function in children with congenital heart disease before intervention.As a sensitive index for clinical detection, it has clinical application value. Key words: Heart defects, congenital; Angioplasty, balloon, coronary; Preoperative period; Natriuretic peptide, brain; Ventricular function, left; Child

The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.

This study aims to investigate the clinical value of combined detection of serum soluble epidermal growth factor receptor (sEGFR), cancer antigen 125 (CA125), and human epididymis protein 4 (HE4) in the diagnosis of epithelial ovarian cancer (EOC). From December 2017 to October 2018, the serum samples were obtained from the Affiliated Hospital of Xuzhou Medical University, with 30 patients as EOC group, 30 patients with benign ovarian neoplasms as benign group, and 17 healthy subjects as healthy group. Besides, among 30 EOC patients, 9 serum samples were obtained from pre-operative and post-operative EOC patients. The levels of serum sEGFR were detected by enzyme-linked immunosorbent assay (ELISA), while CA125 and HE4 were detected by enhanced chemiluminescence immunoassay (ECLIA). The diagnostic value was evaluated by receiver operating characteristic (ROC) curve analysis. The levels of serum sEGFR, CA125, and HE4 in EOC group were significantly higher than those in benign group (p<0.05) and healthy group (p<0.05). When using a single tumor marker, the CA125 shows the highest sensitivity (93.30%) and HE4 shows the highest specificity (97.87%). The specificity of combined detection of serum sEGFR, CA125, and HE4 was 100%, which was significantly higher than that using a single tumor marker. The area under the ROC curve (AUC) of combined detection of serum sEGFR, CA125, and HE4 (0.965) was much higher than that of the single detection and higher than that of combined detection of CA125 and HE4 (0.940). Moreover, the level of serum sEGFR in post-operative EOC group was significantly lower than that in the corresponding pre-operative EOC group (p<0.05). Our study shows that combined detection of serum sEGFR, CA125, and HE4 increases the specificity and efficiency in EOC diagnosis, indicating that sEGFR could be a potential biomarker for the diagnosis and prognosis of EOC.

The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.

To explore the clinical value of combined detection of serum tumor markers in lung cancer, including carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), cytokeratin 19 fragment (CYFRA 21-1), neuron specific enolase (NSE), and squamous carcinoma antigen (SCCA). The expression levels were compared among groups, and the combined effects of these tumor markers in the diagnosis of lung cancer were analyzed. In addition, EGFR gene mutations were detected in some patients with NSCLC. There were 776 patients (age 59.78 ± 10.39 years) with lung cancer and 794 controls (age 58.26 ± 15.73 years) included in our study. In this study, tumor markers were detected in lung cancer patients and controls. Individual sensitivity of the tumor markers sorted in descending order were CEA > CYFRA21-1 > CA15-3 > NSE, and the specificities were NSE > CYFRA21-1 > CEA > CA15-3. The combination of CEA + CA15-3 + CYFRA21-1 + NSE ranked the highest in the sensitivity index (75.00%) and specificity index (98.61%) in lung cancer. In adenocarcinoma, the area under the ROC curve (AUROC) of CEA (0.665) and CYFRA21-1 (0.631) were higher than those of CA15-3 (0.559) and NSE (0.507). In squamous carcinoma, the AUC of CYFRA21-1 (0.722) and SCC (0.628) were higher than those of CEA (0.579), CA15-3 (0.524), and NSE (0.552). In small cell carcinoma, the AUC of NSE (0.654) was higher than those of CEA (0.616), CYFRA21-1 (0.555), and CA15-3 (0.482). These serum tumor markers are valuable indicators in the clinical use. The combination of tumor markers can be used as a method to improve the effectiveness of clinical diagnosis for lung cancer.

Combined Detection of Serum Heat Shock Protein-90&amp;lt;i&amp;gt;α&amp;lt;/i&amp;gt; and Prostate Specific Antigen for Prostate Cancer Diagnosis

Objective: To explore the relationship between heat shock protein-90α (HSP-90α) and occurrence of prostate cancer, and clinical value of combined detection of serum HSP-90α and prostate specific antigen (PSA) in the diagnosis of prostate cancer. Method: A total of 30 patients with prostate cancer, 30 patients with benign prostatic hyperplasia (BPH) and 30 healthy men (control group) were selected from September 2018 to September 2019, then to detect levels of serum HSP-90α, total PSA and free PSA (FPSA) by ELISA, serum testosterone level by radioimmunoassay, prostate cancer tissue was removed by operation, and relative expression of tissue HSP-90α protein by Western blot. Results: The levels of serum HSP-90α and total PSA in prostate cancer group were significantly higher than other two groups, and testosterone level was lower than other two groups (P 0.05). It was found by Pearson test that serum HSP-90α was positively correlated with total PSA level (r = 0.659, P = 0.005), while negatively correlated with testosterone level (r = -0.549, P = 0.006). According to TNM stage of prostate cancer, there were 17 cases of stage I - II, 13 cases of stage III - IV, 6 cases of Gleason score 1 - 4, 13 cases of 5 - 7, 11 cases of 8 - 10, tumor diameter range from 0.8 to 6.2 cm, with average of (3.9 ± 1.5) cm. The relative expression of HSP-90α protein in tumor tissue was closely related to TNM stage, Gleason score and tumor diameter (P α and PSA levels for prostate cancer diagnosis was 0.896, and that of single PSA detection was 0.852. Conclusion: Higher expressions of HSP-90α in prostate cancer tissue and serum may be closely related to occurrence and development of prostate cancer, and combined detections of serum HSP-90α and PSA levels are of great significance in improving early diagnosis of prostate cancer.

Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.

BackgroundReactive oxygen species modulator 1 (ROMO1) is recognized to be involved in cell proliferation and is elevated in serum of various cancer patients. However, ROMO1 had little research in distinguishing between malignant pleural effusions (MPEs) and benign pleural effusions (BPEs).MethodsMalignant pleural effusion samples from patients with non–small‐cell lung cancer (NSCLC) and benign pleural effusion (BPE) samples containing tuberculous and inflammatory pleural effusions were collected. The samples were tested for ROMO1, pleural effusion adenosine deaminase (pADA), pleural effusion carbohydrate antigen (pCA125, pCA153, pCA199), pleural effusion ferritin (pFER), and pleural effusion lactate dehydrogenase (pLDH) levels, and the other relevant partial clinical data that were gathered were used to conduct statistical analysis.ResultsThe ROMO1, pCA125, pCA199, pCA153, pADA + ROMO1, pCA153 + ROMO1, pCA125 + ROMO1, and pCA199 + ROMO1 levels in MPE were appreciably higher in comparison with BPE group (all P = .000). The concentration of pADA in MPE was markedly lower than BPE (P = .000). When the cutoff = 0.38, the sensitivity of combined detection of ROMO1 + pADA is 98.67% and the specificity is 70.73%, respectively, and the AUC (0.941) is the highest among other parameters.ConclusionThe combined detection of ROMO1 + ADA in pleural effusion is an effective biomarker for identifying MPE caused by NSCLC.

The clinical value of combined detection of serum angiopoietin 2 and Clara cell protein 16 in the early diagnosis of acute respiratory distress syndrome

Objective To investigate the clinical value of combined detection of serum angiopoietin 2 (Ang-2) and Clara cell protein 16 (CC16) in the early diagnosis of acute respiratory distress syndrome (ARDS). Methods Two hundred critical patients, treated at the Department of Critical Care Medicine, Bao'an District People's Hospital, Shenzhen during March 2015 and September 2016,were included in the study. According to the Berlin standard, patients were divided into two groups (n=100 each group): the ARDS group and non-ARDS group.The serum levels of Ang-2 and CC16 were measured by enzyme-linked immunosorbent assay (ELISA) on the first and second day of admission for each patient, in addition to completing APACHEⅡ score, medical history, vital signs collection and other biochemical indicators detection. Finally, paired-samples t test was used to analyze the data. The multiple ROC curve was used to calculate the area under the curve of the reference index of the serum levels of Ang-2 and CC16 on the first and second day. Results On the first and second day, the serum levels of Ang-2 and CC16 were significantly higher in ARDS patients than those in non-ARDS patients, and there was a correlation between the serum levels of Ang-2 and CC16 in ARDS patients. The ROC curve showed that the combined detection of Ang-2 and CC16 on the first day achieved a highest sensitivity of 75.9% and detection of CC16 on the first day achieved a highest specificity of 70.2%. Conclusion Single-detection of serum levels of Ang-2 and CC16 could be used for early diagnosis of ARDS, and the combined detection of both has a higher sensitivity than single detection. Key words: Angiopoietin 2; Clara cell protein 16; Acute respiratory distress syndrome; Combined detection; Early diagnosis

T cell receptor rearrangement excision circles (TRECs) and CD31+ regulatory T cells for assessing recent thymic output in patients with chronic hepatitis B

Objective To evaluate the clinical value of combined detection of T cell receptor rearrangement excision circles (TRECs) and CD31+ regulatory T (Treg) cells for accessing the recent thymic output in patients with chronic hepatitis B. Methods Four groups involving 135 subjects were set up in this study as follows: mild chronic hepatitis B (Mild CHB, n=35), moderate chronic hepatitis B (Moderate CHB, n=35), severe chronic hepatitis B (Severe CHB, n=35) and healthy control (HCs, n=30) groups. CD4+ CD25+ Treg cells in these subjects were sorted out using magnetic cell separation. The ratio of peripheral CD31+ Treg cells to Treg cells in each group was analyzed by flow cytometry. Real-time PCR was performed to detect TRECs in CD4+ CD25+ Treg cells. The percentages of CD3+ , CD4+ and CD8+ T cell subsets were also measured. Results The ratios of CD31+ Treg/Treg cells and the numbers of TRECs in peripheral blood of the Moderate CHB and Severe CHB groups were significantly lower than those of the Mild CHB and HCs groups (P 0.05). No significant difference in the percentages of CD3+ , CD4+ or CD8+ T cell subsets was observed between the four groups (P>0.05). CD31+ Treg/Treg cell ratio had a positive correlation with the number of TRECs (r=0.551, P=0.014). Conclusions Both CD31+ Treg/Treg cell ratio and the number of TRECs were reduced in the peripheral blood of patients with moderate or severe CHB. CD31+ Treg/Treg cell ratio and the number of TRECs were positively correlated and could be used as new indices to evaluate recent thymus output. Key words: Chronic hepatitis B; CD4+ CD25+ regulatory T cell; CD31+ regulatory T cell; T cell receptor rearrangement excision circles

Clinical value of combined detection of serum CEA, CA199, CA125 in the diagnosis of lung cancer

Objective To investigate the diagnostic value of combined detection of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and carbohydrate antigen 125 (CA125) in lung cancer. Methods From July 2017 to February 2019, 64 patients with lung cancer, 40 cases of benign pulmonary lesions and 40 healthy people were selected by random lottery in Fuyang Hospital Affiliated to Anhui Medical University.Serum CEA, CA199 and CA125 levels of each group were analyzed. Results The levels of serum CEA, CA199 and CA125 in patients with lung cancer were significantly higher than those in patients with benign lung disease, the differences were statistically significant (t=18.355, P<0.001; t=11.757, P<0.001; t=10.754, P<0.001). The serum CA125 of lung benign disease group was significantly higher than the healthy group, and the difference was statistically significant(t=6.942, P<0.001). The positive rates of serum CEA, CA199 and CA125 in patients with lung cancer were significantly higher than those in the benign lung disease group and healthy group, the differences were statistically significant(χ2=22.110, P<0.001; χ2=13.321, P=0.002; χ2=15.125, P=0.001). The serum levels of CEA, CA199, and CA125 in patients with middle and advanced stage were significantly higher than those in the early stage, the differences between the advanced group and the early group were statistically significant (t=5.587, P<0.001; t=5.068, P<0.001; t=8.962, P<0.001). Those between the mid-term group and the early group had statistically significant differences (t=4.44, P<0.001; t=4.716, P<0.001; t=12.700, P<0.001). The CEA level of patients with advanced lung cancer was significantly higher than that of the intermediate patients.There was statistically significant difference in the CEA level between the advanced group and the mid-term group (t=3.860, P=0.001). Serum CA125 was the most sensitive in the diagnosis of lung cancer (60.84%), but had the lowest specificity (65.17%). CA125 compared with CA199, CEA, the difference was statistically significant (sensitivity: χ2=10.723, P<0.001 specificity: χ2=4.203, P=0.023). The sensitivity of CEA+ CA199+ CA125 combined detection was significantly higher than single detection, the difference was statistically significant(χ2=26.047, P<0.001), Conclusion The combined detection of serum CEA, CA125 and CA199 has high sensitivity in the diagnosis of lung cancer, which can improve the detection rate of early lung cancer and is worthy of clinical application. Key words: Lung neoplasms; Carcinoembryonic antigen; Antigens, tumor-associated, carbohydrate; Tumor markers, biological; Sensitivity; Specificity

Significance of T-cell dot test and combined detection of adenosine deaminase in tuberculous pleurisy at different ages

Objective To analyze the clinical value of combined detection of tuberculous T cell enzyme-linked immuno spot assay (T-SPOT.TB) and adenosine deaminase (ADA) in tuberculous pleurisy patients of different ages. Methods From February 2014 to February 2018, three hundred and thirty-six patients with pleural effusion were admitted to Hebei Thoracic Hospital.Among them, two hundred and fifty five cases were diagnosed as tuberculous pleurisy and 81 cases were diagnosed as non-tuberculous pleurisy.The patients were divided into two groups according to their age.The younger group (214 cases) was 16-59 years old and the older group (122 cases) was over 60 years old.The sensitivity and specificity of T-SPOT.TB combined with ADA in the diagnosis of tuberculous pleurisy were compared between the two groups. Results The sensitivity and specificity of T-SPOT.TB were 85.5% (153/179) and 71.4% (25/35) in the young and middle-aged group, 73.7% (56/76) and 58.7% (27/46) in the old group, respectively.The sensitivity of the young and middle-aged group was significantly higher than that of the old group (χ2=4.990, P=0.045). The sensitivity and specificity of T-SPOT.TB combined with ADA were 98.9% (177/179) and 94.3% (33/35) in the young and middle-aged group, 96.1% (73/76) and 89.1% (41/46) in the elderly group, respectively.There was no significant difference in sensitivity and specificity between the two groups (χ2=0.256, P=0.393、χ2=0.655, P=0.218). Conclusion The diagnostic efficacy of T-SPOT.TB combined with ADA in patients with tuberculous pleurisy at different ages has been improved, especially for those who can not tolerate pleural biopsy and elderly patients. Key words: Tuberculous pleurisy; T cell enzyme-linked immuno-spot assay; Adenosine deaminase; Age

Clinical value of combined detection of miR-1202 and miR-195 in early diagnosis of cervical cancer.

The clinical value of the combined detection of miR-1202 and miR-195 in the early diagnosis of cervical cancer was studied. A retrospective analysis of 70 cervical cancer patients treated in the The Third Affiliated Hospital of Kunming Medical University and Yunnan Cancer Hospital from October 2015 to December 2017 was performed, and the lesion tissues were used as the experimental group. Normal cervical tissues from another 67 healthy females confirmed by physical examination at the same period were selected as the control group. The FIGO staging criteria were used for staging of the cervical cancer patients, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) method was used for the detection of the expression of miR-1202 and miR-195 in different tissues, and the receiver operating curve (ROC) was used for the analysis of the application values of miR-1202 and miR-195 diagnosis alone and their combined diagnosis in early cervical cancer patients. The levels of miR-1202 and miR-195 in the experimental group were lower than those in the control group (P<0.05). The differences were significant in the different stages of cervical cancer tissues (P<0.05). The later the staging of cervical cancer tissues were, the lower the levels of miR-1202 and miR-195 were. The sensitivities and area under the curve (AUC) values of miR-1202 and miR-195 in the combined diagnosis of early cervical cancer were significantly higher than those of miR-1202 and miR-195 alone. The expression levels of miR-1202 and miR-195 in the cervical cancer patients are different in different stages. Guiding clinical treatment and prognosis according to the results of combined detection is beneficial for the development of treatment for cervical cancer patients and for prognostic judgement, worthy of popularization and application.

Clinical application value of combined detection of serum miR-378 and miR-21 in gastric cancer

Objective: To investigate the clinical value of combined detection of serum miR-378 and miR-21 in gastric cancer (GC). Methods: Eighty-seven patients with GC and 78 patients with colorectal cancer(CRC) from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences were selected, 83 individuals undergoing healthy physical examination were selected as the healthy controls. The levels of serum miR-378 and miR-21 were detected by quantitative real-time PCR (RT-qPCR) (result data were transformed as log2 for analysis). Results: Relative expression levels of miR-378 in the serum were -1.24, -3.25 and -2.73 in healthy controls, GC and CRC patients, respectively. Compared with the healthy controls, the levels of serum miR-378 were significantly decreased in GC and CRC patients (both P<0.05). Relative expression levels of miR-21 in the serum were 0.11, 2.34 and 2.47 in healthy controls, GC and CRC patients, respectively. Compared with the healthy controls, the levels of serum miR-21 were significantly up-regulated in GC and CRC patients (both P<0.05). Moreover, the serum level of miR-378 in GC patients was inversely associated with tumor clinical stage (P<0.05). However, the level of miR-21 showed no significant differences among patients with different clinical and pathological characteristics (all P>0.05). The area under the receiver operating characteristic curve (AUC), sensitivity and specificity of miRNA-378 to diagnose GC was 0.770, 82.0% and 66.0%, respectively, and were 0.900, 85.0%, and 88.0% of miR-21, respectively. The AUC, sensitivity and specificity of combined detection of serum miR-378 and miR-21 to diagnose GC were 0.930, 92.0% and 87.0%, respectively, while the AUC of combined detection of serum CEA and CA-199 was 0.767, the AUC of combined all of the four factors was 0.946. Conclusion: The combined detection of serum miR-378 and miR-21 have a certain effect on diagnosis of GC.

Clinical value of combined detection of serum APE1-Aabs and CEACAM-1 in the diagnosis of colorectal cancer.

To analyze the clinical value of combined detection of serum APE1-Aabs and CEACAM-1 in pathological diagnosis of colorectal cancer. From December 2014 to July 2016, 60 patients with colorectal cancer and 50 healthy subjects were enrolled in this study. The levels of APE1-AAbs, CEACAM-1 and CEA in the serum were measured, and the clinical value of each index in the diagnosis of colorectal cancer was analyzed. The level of serum APE1-AAbs in colorectal cancer group was significantly higher than that in healthy control group (p < 0.05). The levels of serum CEACAM-1 and CEA in colorectal cancer patients were significantly higher than those in healthy control group (p < 0.05). The sensitivity and accuracy of APE1-AAbs and CEACAM-1 in the diagnosis of colorectal cancer were significantly higher than separate detection of APE1-AAbs, CEACAM-1 or CEA. Combined detection of serum APE1-AAbs and CEACAM-1 has the advantages of high sensitivity and good accuracy in the diagnosis of colorectal cancer, and it is worthy to be popularized in clinical practice.